← Leaderboards
Frank T Martiniuk
New York University School Of Medicine
$42,012
Attributed
$42,012
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$42,012 · 7
By mechanism
M01$42,012 · 7
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Ira Jay Goldberg$42,989,404
- Carmen V Melendez-Vasquez$3,058,804
- Michael L Dustin$32,535,535
- Shukti Chakravarti$13,351,356
- James L Salzer$22,072,768
Others in their field
Top investigators on “Glucan 1,4 Alpha Glucosidase”
- Dwight D Koeberl · Duke University$7,052,398
- Luc Teyton · Scripps Research Institute, The$2,916,161
- Barry J. Byrne · University Of Florida$2,645,354
- Mai Elmallah · University Of Florida$2,273,958
- Sathy Venkat Balu-Iyer · State University Of New York At Buffalo$1,961,840
- David D Fuller · University Of Florida$1,677,958
Research focus
Glucan 1,4 Alpha GlucosidaseGlycogen Storage Disease Type IiNucleic Acid SequenceGene TherapyOligonucleotidesRecombinant DnaCytomegalovirusHuman Genetic Material TagTransfection /Expression VectorCreatine KinaseMyosinsLaboratory MouseNonhuman Therapy EvaluationGene MutationHuman SubjectPathologic ProcessComplementary DnaEnzyme ActivityMyocardiumGenetic Regulatory ElementAnimal TissueClinical ResearchGenetically Modified AnimalsHuman Tissue
Grant awards (18)
NOVEL MUSCLE SPECIFIC VECTOR FOR GENE THERAPY OF ACID MALTASE DEFICIENCY$0
M01 · FY2002 · RR
GLYCOGENOSIS TYPE II--MOLECULAR ANALYSIS OF PATIENTS$0
M01 · FY2002 · RR
NOVEL MUSCLE SPECIFIC VECTOR FOR GENE THERAPY OF ACID MALTASE DEFICIENCY$0
M01 · FY2001 · RR
GLYCOGENOSIS TYPE II--MOLECULAR ANALYSIS OF PATIENTS$0
M01 · FY2001 · RR
NOVEL MUSCLE SPECIFIC VECTOR FOR GENE THERAPY OF ACID MALTASE DEFICIENCY$21,006
M01 · FY2000 · RR
GLYCOGENOSIS TYPE II--MOLECULAR ANALYSIS OF PATIENTS$21,006
M01 · FY2000 · RR
MUSCLE PROMOTERS --ACID MALTASE DEFICIENCY GENE THERAPY$0
M01 · FY2000 · RR
NOVEL MUSCLE SPECIFIC VECTOR FOR GENE THERAPY OF ACID MALTASE DEFICIENCY$0
M01 · FY2000 · RR
UNDESCRIBED DRUG RESISTANCE GENES IN TUBERCULOSIS$0
M01 · FY2000 · RR
UNDESCRIBED DRUG RESISTANCE GENES IN TUBERCULOSIS$0
M01 · FY2000 · RR
PRODUCTION OF RECOMBINANT HUMAN ACID MALTASE IN PLANTS$0
M01 · FY2000 · RR
PRODUCTION OF RECOMBINANT HUMAN ACID MALTASE IN PLANTS$0
M01 · FY2000 · RR
MUSCLE PROMOTERS --ACID MALTASE DEFICIENCY GENE THERAPY$0
M01 · FY2000 · RR
GLYCOGENOSIS TYPE II--MOLECULAR ANALYSIS OF PATIENTS$0
M01 · FY2000 · RR
LIPOSOMAL GENE DELIVERY FOR ACID MALTASE DELIVERY$0
M01 · FY2000 · RR
LIPOSOMAL GENE DELIVERY FOR ACID MALTASE DELIVERY$0
M01 · FY2000 · RR
ACID MALTASE DEFICIENCY--GENE ENZYME REPLACEMENT THERAPY$0
M01 · FY2000 · RR
ACID MALTASE DEFICIENCY--GENE ENZYME REPLACEMENT THERAPY$0
M01 · FY2000 · RR